Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder
| Autor: | Keith Burling, Elaine W. Kay, Peter A. Dervan, Amanda McCann, Jenny A. Watson, Patricia Fitzpatrick, John M. Fitzpatrick, John D. Kelly |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Nephrology medicine.medical_specialty Pathology Adolescent Urology Urinary system Enzyme-Linked Immunosorbent Assay Urine Sensitivity and Specificity Cohort Studies Young Adult fluids and secretions Insulin-Like Growth Factor II Predictive Value of Tests Internal medicine Biomarkers Tumor Carcinoma medicine Humans Aged Aged 80 and over Carcinoma Transitional Cell Bladder cancer medicine.diagnostic_test business.industry Nuclear Proteins Cystoscopy Gold standard (test) Middle Aged medicine.disease Urinary Bladder Neoplasms embryonic structures Biomarker (medicine) Female business |
| Zdroj: | BJU International. 103:694-697 |
| ISSN: | 1464-410X 1464-4096 |
| DOI: | 10.1111/j.1464-410x.2008.08213.x |
| Popis: | OBJECTIVE To examine urinary insulin-like growth factor 2 (IGF-2) levels in patient urine samples and determine the potential of IGF-2 as a marker for the presence of urothelial carcinoma of the bladder (UCB). PATIENTS AND METHODS The current gold standard for diagnosis of UCB is cystoscopy and cytological analysis. The identification of an accurate urine marker for UCB with the potential to replace unnecessary cystoscopy would benefit patients with UCB and others investigated after detecting haematuria. In the present study, we analysed 65 urine samples, and optimized an enzyme-linked immunosorbent assay-based approach to measure urinary levels of IGF-2. RESULTS Based on a threshold of 5.4 ng/mL, patients with UCB have significantly elevated levels of urinary IGF-2 (P = 0.009) and this difference remained significant after adjustment for age and sex (P = 0.04). Sensitivity and specificity values of 80% and 52%, respectively, were determined for urinary IGF-2 alone and when combined with nuclear matrix protein 22 (NMP22; an approved biomarker for detection of UCB). There was a positive correlation between urinary IGF-2 levels and NMP22 levels in patient urine samples and the combined assay improved the detection of UCB (sensitivity 85% and specificity 52%). CONCLUSION Substantiated evidence has identified IGF-2 as a valuable marker for UCB. In addition, the novel observations of the present study have shown that aberrant levels of IGF-2 occurring in the presence of UCB, can now be determined through a simple and inexpensive urine assay. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|